Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 10/20 | 0.43 |
| ▸ | PPARA | Q07869 | 8/20 | 0.43 |
| ▸ | PPARG | P37231 | 7/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198943 | 0.86 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2PPARDPPARAPPARG | |
| SCHEMBL4471873 | 0.85 | MAPT (0.45) | ALDH1A1SMN1; SMN2PPARDPPARAPPARG | |
| SCHEMBL1508353 | 0.85 | NPC1 (0.58) | ALDH1A1PPARDPPARAPPARGMAPT | |
| SCHEMBL6388947 | 0.76 | MPL (0.43) | ALDH1A1SMN1; SMN2PPARDPPARAPPARG | |
| SCHEMBL5017176 | 0.76 | PPARD (0.57) | ALDH1A1PPARDPPARAPPARGMAPT | |
| SCHEMBL8989130 | 0.76 | KDM4E (0.54) | PPARDMAPTGAAFFAR1 | |
| SCHEMBL3372790 | 0.75 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2PPARDPPARAPPARG | |
| SCHEMBL8867441 | 0.75 | SMN1; SMN2 (0.76) | ALDH1A1SMN1; SMN2PPARAMAPTNPC1 | |
| SCHEMBL3527473 | 0.74 | PPARD (0.42) | ALDH1A1PPARDPPARAPPARGMAPT | |
| SCHEMBL3371906 | 0.74 | MAPT (0.55) | ALDH1A1PPARDPPARAPPARGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-7259175-B2 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-08-21 | — | — | US | disclosed |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| US-20060166983-A1 | Indole derivatives as ppar modulators | ELI LILLY AND COMPANY | 2006-07-27 | — | — | US | disclosed |
| US-20060084663-A1 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY, PATENT DIVISION (US) | 2006-04-20 | — | — | US | disclosed |
| EP-1581491-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1581521-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1480642-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004092131-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004063190-A1 | FUSED HETEROCYCLIC DERIVATES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2003072102-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166983-A1 | Indole derivatives as ppar modulators | PPARA, PPARD, PPARG | ALDH1A1 1181/4885SMN1; SMN2 4874/4885PPARD 2/4885 |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | PPARG, PPARA, PPARD | ALDH1A1 1182/4885SMN1; SMN2 4859/4885PPARD 3/4885 |
| US-20060084663-A1 | Peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | ALDH1A1 1630/4885SMN1; SMN2 3832/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.